# A Safety Study of Mirikizumab (LY3074828)

> **NCT01947933** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 45 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** Mirikizumab- IV
- **BIOLOGICAL:** Mirikizumab - SC
- **BIOLOGICAL:** Placebo - IV

## Key facts

- **NCT ID:** NCT01947933
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01947933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01947933, "A Safety Study of Mirikizumab (LY3074828)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01947933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*